Dec 1, 2022
NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted CAR T Cell MCARH125 NCT05431608: Phase 1: A Study of MCARH109 and MCARH125 in...
256
Dec 1, 2022
NCT05243797: Phase 3: EMN 30 - Tec + Len Vs Len Alone NDMM as Maint. Therapy Post ASCT (MajesTEC-4)
EMN30 - MajesTEC-4 64007957MMY3003 NCT05243797: Phase 3: Teclistamab + Lenalidomide Versus Lenalidomide Alone in NDMM Myeloma as...
1,344
Dec 1, 2022
NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for Myeloma in Patients Progressing on CAR-T
NCT05204160: Phase 2: Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell...
119
Dec 1, 2022
Dana-Farber's 2022 Multiple Myeloma Patient Symposium - Update on Multiple Myeloma Treatment
Watch on You Tube Update on Multiple Myeloma Treatment: Kenneth C. Anderson, MD Jan 19, 2022 Dana-Farber Cancer Institute Learn more:...
216
Dec 1, 2022
NCT05218603: Bortezomib Plus Daratumumab (V-Dara) After Induction With VMP-Dara - NDMM -TIE Myeloma
NCT05218603: Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone...
91
Dec 1, 2022
The ESMO Virtual Plenaries - IKEMA Updated Analysis - Latest Data in Multiple Myeloma
The ESMO Virtual Plenaries The ESMO Virtual Plenaries - IKEMA Updated Analysis - Latest Data in Multiple Myeloma Learn more:...
61
Dec 1, 2022
How to Prevent Neutropenic Sepsis on Treatment? Know Your ANC (Absolute Neutrophil Count)
Low ANC Count is a risk for developing infections, while getting cancer treatments. Monitoring Your ANC helps you prevent infections....
151
Dec 1, 2022
#COMY22 - Myeloma Abstracts - COMy World Congress Paris, France - May 12-15, 22
The 8th COMy World Congress – Paris, France & Online, May 12 - 15, 2022 #COMY 22 - MYELOMA ABSTRACTS The 8th COMy World Congress – Paris,...
320
Dec 1, 2022
NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After BCMA CART Therapy for RRMM
NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell...
50
Dec 1, 2022
You are central to the care team: Be Empowered - IMF Patient & Family Webinar - May 14, 2022
IMF Patient & Family Webinar - New Frontiers In Myeloma Care, May 14, 2022 You are central to the care team: Be Empowered Watch Video on...
131
Dec 1, 2022
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma
NCT05182073: Phase 1: FT576 in Subjects With Multiple Myeloma FT576 in Subjects With Multiple Myeloma This is a Phase I dose-finding...
218
Dec 1, 2022
NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With RRMM Myeloma or Plasma Cell Leukemia
NCT05219721: Phase 1: A Study of CAR-GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia NCT05219721:...
111
Dec 1, 2022
NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed Refractory MM
NCT05308225: Phase 1/2: Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma This is a two-stage...
319
Dec 1, 2022
#ASCO22 Myeloma Abstracts - 2022 ASCO Annual Meeting: JUNE 3-7, 2022 Chicago, IL
2022 ASCO Annual Meeting: JUNE 3-7, 2022 Chicago, IL #ASCO22 Myeloma Abstracts June 3-7, 2022 McCormick Place • Chicago, IL, Online...
270
Dec 1, 2022
NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Cilta-Cel CART
NCT05201781: Phase 4: A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel NCT05201781: Phase 4: A...
78
Dec 1, 2022
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma The...
166
Dec 1, 2022
International Academy for Clinical Hematology (IACH) Journal Club - May 17, 2022 - 07:00 PM Paris
International Academy for Clinical Hematology (IACH) Journal Club May 17, 2022 07:00 PM Paris Minimal Residual Disease After Autologous...
104
Dec 1, 2022
NCT05259839: Phase 1: IV Infused ABBV-383 With Anti-Cancer Regimens for Relapsed/Refractory Myeloma
NCT05259839: Phase 1: (IV) Infused ABBV-383 in Combination With Anti-Cancer Regimens for Relapsed/Refractory Multiple Myeloma A Study to...
484
Dec 1, 2022
NCT05354557: Phase 2 - Study of Iberdomide in Multiple Myeloma Post ASCT Transplant
NCT05354557: Phase 2 - Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant...
98